Search research articles
Contact Us
Filters
Showing results (41-50 of 215) with videos related to
Page
of 22
Sort By:
Molecular Cancer Therapeutics
|
November 9, 2005
Clinical translation of epigenetics in cancer: eN-CORe--a report on the second workshop
Arthur Zelent, Kevin Petrie, Reuben Lotan, et al.
Current Opinion in Hematology
|
January 12, 2019
What are the most promising new agents in myelodysplastic syndromes?
Namrata S Chandhok, Prajwal C Boddu, Steven D Gore, et al.
Blood Reviews
|
June 30, 2015
The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions
Eun-Ju Lee, Nikolai Podoltsev, Steven D Gore, et al.
Blood Reviews
|
October 18, 2016
Selecting initial treatment of acute myeloid leukaemia in older adults
Nikolai A Podoltsev, Maximilian Stahl, Amer M Zeidan, et al.
Current Opinion in Hematology
|
January 10, 2015
Current state of prognostication and risk stratification in myelodysplastic syndromes
Amer M Zeidan, Steven D Gore, Eric Padron, et al.
The American Journal of Medicine
|
March 20, 2013
Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS)
Amer M Zeidan, B Douglas Smith, Rami S Komrokji, et al.
Cancer Chemotherapy and Pharmacology
|
December 26, 2006
Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL
Tamer E Fandy, Douglas D Ross, Steven D Gore, et al.
Hematology. American Society of Hematology. Education Program
|
November 25, 2003
Myelodysplastic syndrome
Ghulam Mufti, Alan F List, Steven D Gore, et al.
Blood Reviews
|
September 29, 2020
Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst
Rory M Shallis, Julian J Weiss, Nicole C Deziel, et al.
Blood Reviews
|
August 11, 2020
A clandestine culprit with critical consequences: Benzene and acute myeloid leukemia
Rory M Shallis, Julian J Weiss, Nicole C Deziel, et al.
Page
of 22
Search research articles
Search
Showing results (41-50 of 215) with videos related to
Sort By:
Page
of 22
Molecular Cancer Therapeutics
|
November 9, 2005
Clinical translation of epigenetics in cancer: eN-CORe--a report on the second workshop
Arthur Zelent, Kevin Petrie, Reuben Lotan, et al.
Current Opinion in Hematology
|
January 12, 2019
What are the most promising new agents in myelodysplastic syndromes?
Namrata S Chandhok, Prajwal C Boddu, Steven D Gore, et al.
Blood Reviews
|
June 30, 2015
The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions
Eun-Ju Lee, Nikolai Podoltsev, Steven D Gore, et al.
Blood Reviews
|
October 18, 2016
Selecting initial treatment of acute myeloid leukaemia in older adults
Nikolai A Podoltsev, Maximilian Stahl, Amer M Zeidan, et al.
Current Opinion in Hematology
|
January 10, 2015
Current state of prognostication and risk stratification in myelodysplastic syndromes
Amer M Zeidan, Steven D Gore, Eric Padron, et al.
The American Journal of Medicine
|
March 20, 2013
Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS)
Amer M Zeidan, B Douglas Smith, Rami S Komrokji, et al.
Cancer Chemotherapy and Pharmacology
|
December 26, 2006
Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL
Tamer E Fandy, Douglas D Ross, Steven D Gore, et al.
Hematology. American Society of Hematology. Education Program
|
November 25, 2003
Myelodysplastic syndrome
Ghulam Mufti, Alan F List, Steven D Gore, et al.
Blood Reviews
|
September 29, 2020
Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst
Rory M Shallis, Julian J Weiss, Nicole C Deziel, et al.
Blood Reviews
|
August 11, 2020
A clandestine culprit with critical consequences: Benzene and acute myeloid leukemia
Rory M Shallis, Julian J Weiss, Nicole C Deziel, et al.
Page
of 22